It has been a very rough start to 2016 on the capital markets with the Dow Jones Industrial average shedding almost 3 percent of its value in the wake of geopolitical and macroeconomic uncertainties – but this hasn't seemed to deter both public and private biotech companies from their plans to boost their cash balances. Read More
LONDON – Complix NV has reached a major inflexion point in the development of its alphabody technology, signing the first pharma partner in a deal with a headline value of $280 million. Read More
Rodin Therapeutics Inc. has landed a multi-year neuronal epigenetics R&D deal with Biogen Inc. that includes an undisclosed up-front payment for an option to buy the small cognitive disorders specialist as well as potential milestone payments of up to $485 million should the acquisition come to pass. Read More
Better mechanisms and clearer regulatory guidance are making way for new pain drugs, Quartet Medicine Inc. CEO Kevin Pojasek told BioWorld Today, talking about his firm's potential $595 million deal with Merck & Co. Inc. with a small-molecule approach to pain that targets the tetrahydrobiopterin (BH4) pathway. Read More
Inhibiting the bromodomain and extra-terminal motif (BET) protein BRD4 led to regression in xenograft models of triple-negative breast cancer (TNBC), a study published online in the Jan. 6, 2015, issue of Nature showed. Read More
LONDON – April 2016 may mark 10 years since the first biosimilar was approved in Europe, but the latest research indicates the market is far from mature. Uptake and price reductions vary markedly both between countries and product categories, and overall there is little correlation between market share and price cuts. Read More
SHANGHAI – Canbridge Life Sciences Inc. has confirmed the existence of ligand CD95 in Chinese glioblastoma patients after completing the first such biomarker study of its kind on the mainland. The study demonstrated a high degree of CD95 ligand expression consistency between geographically diverse Chinese and Western glioblastoma multiforme patients. Read More
Reiterating that drugs sold via the Internet must comply with the same sales and distribution rules as those sold conventionally, the Central Drugs Standard Control Organisation (CDSCO) is instructing state drug controllers in India to crack down on Internet drug sales. Read More
Peregrine Pharmaceuticals Inc., of Tustin, Calif., said it signed a new research collaboration with the National Comprehensive Cancer Network (NCCN) to expand the company's ongoing clinical research and development of bavituximab, which is designed to target phosphatidylserine, for the treatment of a range of tumors. Read More
Effector Therapeutics Inc., of San Diego, initiated dosing in a phase I/II dose-escalation and cohort-expansion study of eFT508 in patients with advanced solid tumors. The trial is evaluating the safety, pharmacokinetics, pharmacodynamics and antitumor activity of daily oral eFT508 in patients with advanced solid tumors. Read More
